glp 1 injection site reactions GLP-1 Dermatologic Effects: What Clinicians Should Know Reacciones en el sitio de
Description
DM: diabetes mellitus
7 Tirzepatide is a unimolecular, bifunctional peptide invented by Eli Lilly and Company (Indianapolis, IN, USA), which simultaneously activates GLP-1R and GIPR
While these drugs have been on the market quite a while for the treatment of Type 2 diabetes, they are a fairly new medication for the purposes of weight loss alone and for those just looking to lose a few pounds
For example, the LEADER trial showed that Liraglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by 13% and cardiovascular death by 22% in comparison to placebo
